SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announced today the appointment of Northland Capital Partners to act as the Company’s Joint Corporate Broker, alongside Turner Pope Investments, with immediate effect.
SkinBioTherapeutics plc is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain. The platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The company received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix Health plc(LON:OPTI).
